Gardasill 9™ vaccine — Competitive Intelligence Brief

Gardasill 9™ vaccine (Gardasill 9™ vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant virus-like particle vaccine. Area: Oncology / Immunology.

phase 3 Recombinant virus-like particle vaccine Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 Oncology / Immunology Biologic

Target snapshot

Gardasill 9™ vaccine (Gardasill 9™ vaccine) — Imperial College London. Gardasil 9 is a recombinant vaccine that stimulates the immune system to produce antibodies against nine types of human papillomavirus (HPV) to prevent infection and associated cancers.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gardasill 9™ vaccine TARGET	Gardasill 9™ vaccine	Imperial College London	phase 3	Recombinant virus-like particle vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
quadrivalent HPV vaccine	quadrivalent HPV vaccine	International Agency for Research on Cancer	marketed	Recombinant virus-like particle vaccine	HPV types 6, 11, 16, 18 (L1 major capsid protein)
Human papillomavirus quadrivalent vaccine	Human papillomavirus quadrivalent vaccine	University of Alberta	marketed	Recombinant virus-like particle vaccine	Human papillomavirus types 6, 11, 16, and 18 (L1 capsid protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant virus-like particle vaccine class)

1. Imperial College London · 1 drug in this class
2. International Agency for Research on Cancer · 1 drug in this class
3. University of Alberta · 1 drug in this class